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Abstract
A study of workers exposed to jet fuel propellant 8 (JP-8) was conducted at U.S. Air Force bases 
and included the evaluation of three biomarkers of exposure: S-benzylmercapturic acid (BMA), S-
phenylmercapturic acid (PMA), and (2-methoxyethoxy)acetic acid (MEAA). Postshift urine 
specimens were collected from various personnel categorized as high (n = 98), moderate (n = 38) 
and low (n = 61) JP-8 exposure based on work activities. BMA and PMA urinary levels were 
determined by high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/
MS), and MEAA urinary levels were determined by gas chromatography–mass spectrometry (GC-
MS). The numbers of samples determined as positive for the presence of the BMA biomarker 
(above the test method’s limit of detection [LOD = 0.5 ng/ml]) were 96 (98.0%), 37 (97.4%), and 
58 (95.1%) for the high, moderate, and low (control) exposure workgroup categories, respectively. 
The numbers of samples determined as positive for the presence of the PMA biomarker (LOD = 
0.5 ng/ml) were 33 (33.7%), 9 (23.7%), and 12 (19.7%) for the high, moderate, and low exposure 
categories. The numbers of samples determined as positive for the presence of the MEAA 
biomarker (LOD = 0.1 μg/ml) were 92 (93.4%), 13 (34.2%), and 2 (3.3%) for the high, moderate, 
and low exposure categories. Statistical analysis of the mean levels of the analytes demonstrated 
MEAA to be the most accurate or appropriate biomarker for JP-8 exposure using urinary 
concentrations either adjusted or not adjusted for creatinine; mean levels of BMA and PMA were 
not statistically significant between workgroup categories after adjusting for creatinine.
Biomarkers of exposure are important tools for use in exposure assessment and toxicological 
research. As the term implies, biomarkers of exposure are those related to exposure and the 
internal levels of some agent or chemical. A well-chosen biomarker of exposure should have 
several qualities. Primarily, the biomarker should be specific for the exposure of interest; 
some metabolites are common to multiple parent chemical substances and therefore may not 
be suitably specific biomarkers. Second, the biomarker needs to be associated with the 
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exposure, and it needs to provide good predictive value to a specific health status. Third, a 
biomarker needs to have reference values in the population if possible (B’Hymer and 
Cheever 2010). With these qualities being considered, JP-8, the primary fuel used by the 
Department of Defense, becomes an interesting challenge with respect to assessing 
exposure. JP-8 is a kerosene-based complex chemical mixture containing hundreds of 
aliphatic and aromatic hydrocarbons with various isomer forms plus several additives 
(Ritchie et al. 2003). The fuel is formulated to meet military performance specifications, and 
therefore, the overall chemical composition varies from batch to batch with the exception of 
an anti-icing component (NRC 2003). With the many constituent chemicals present at 
varying concentrations, the best or most accurate biomarker for JP-8 exposure has not been 
extensively addressed in the literature, and this was the main objective of the current study. 
Three potential biomarkers of JP-8 exposure were compared since a previous study had 
investigated only one of these potential biomarkers (B’Hymer et al. 2012).
The specifications for JP-8 include a maximum olefin content of 5%, a maximum aromatic 
content of 22%, and a maximum sulfur content of 0.3%. On average, the composition is 
approximately 33–61% alkanes, 10–45% cycloalkanes, 12–22% aromatics and 0.5–5% 
olefins (Vere 2003). Toluene and benzene are two important aromatic compounds in JP-8. 
Biotransformation of these two aromatic compounds has been thoroughly studied, and the 
applicability of their metabolites as possible biomarkers of exposure in humans has been 
discussed (Kim et al. 2006; Manini et al. 2004; Qu et al. 2000). Another important 
component of JP-8 is 2-(2-methoxyethoxy)ethanol; this is added to the fuel as an anti-icing 
agent and is formulated at a consistent concentration of 0.1%. 2-(2-Methoxyethoxy)ethanol 
metabolites have been previously discussed with respect to their applicability for possible 
use as JP-8 biomarkers of exposure (B’Hymer and Cheever 2010). The toxicity of many of 
the component chemicals in jet fuel has been well established, and reviews on this topic 
appeared elsewhere (Mattie and Sterner 2011; Ritchie et al. 2003) and thus are not discussed 
further.
Two of the known common urinary metabolites of toluene include S-benzylmercapturic acid 
(BMA) and hippuric acid (Marchese et al. 2004). A simplified metabolic scheme for toluene 
is shown in Figure 1, and a full description of the metabolic pathway can be found elsewhere 
(Rietveld et al. 1983; Angerer et al. 1998). O-Cresol and hippuric acid are the traditional 
urinary metabolites used to measure toluene exposure and are the more abundant 
metabolites of toluene exposure. The American Conference of Governmental Industrial 
Hygienists (ACGIH) has set biological exposure indices (BEI) levels for these two 
compounds. The BEI level for o-cresol is 0.5 mg/L, and the BEI level for hippuric acid is 
1.6 mg/mg creatinine in urine samples collected at the end of a shift (ACGIH 2011). 
However, hippuric acid is not specific to toluene exposure. Other studies showed BMA to be 
the preferred metabolite for use as a biomarker of toluene exposure (Angerer et al. 1998; 
Inoue et al. 2002), and therefore BMA was selected for the current study.
Some of the common urinary metabolites of benzene include S-phenylmercapturic acid 
(PMA), trans,trans-muconic acid (t,t-MA), hydroquinone, catechol, phenol, and 
trihydrobenzene (Qu et al. 2000; Sabourin et al. 1988). A simplified metabolic scheme for 
benzene is shown in Figure 2 and is not described in further detail here. The ACGIH has set 
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recommended BEIs for an end-of-shift urine sample containing PMA at 25 ng/mg creatinine 
and t,t-MA at 500 ng/mg creatinine (ACGIH 2001). Although phenol and its conjugates are 
the more abundant biotransformation products for benzene, these compounds are not 
suitable as specific biomarkers for benzene as they can also be the metabolic products of 
other common chemicals. As with BMA from its parent toluene, PMA is the preferred 
metabolite for use as biomarker for benzene exposure (Lovreglio et al. 2010; Melikian et al. 
1999) and is the target for the current study.
The compound 2-(2-methoxyethoxy) ethanol (also known as diethylene glycol monomethyl 
ether [DiEGME] and under the trade name of methyl carbitol, CAS 111-77-3) is another 
component of JP-8. It is unique in being an additive in the formulation of JP-8 for the 
military and is at a consistent concentration of 0.1% (v/v) for every batch of the fuel as 
previously described. 2-(2-Methoxyethoxy)ethanol, a glycol ether, has a limited number of 
industrial uses, including in formulation of inks and some paints. Although benzene and 
toluene are commonly used in many home products and other fuels, 2-(2-
methoxyethoxy)ethanol is encountered much less frequently in the general environment. The 
corresponding metabolite of this glycol ether is (2-methoxyethoxy)acetic acid (MEAA). 
Because of the low frequency of use of the parent compound, the MEAA metabolite has not 
been detected in the general population and should not appear in any significant quantity in a 
control population. MEAA has been studied for use as a biomarker previously in both 
humans (B’Hymer et al. 2012) and animals (B’Hymer et al. 2005a; Richards et al. 1993). It 
has also been demonstrated that MEAA is the urinary metabolite best suited for use as a 
short-term biomarker for exposure to 2-(2-methoxyethoxy)ethanol (Richards et al. 1993). 
Animal studies demonstrated a rapid conversion of the parent compound to MEAA (Daniel 
et al. 1991; Richards et al. 1993). The metabolism of 2-(2-ethoxyethoxy)ethanol is complex, 
and the mechanism based on animal studies (Cheever et al. 1988; Sumner et al. 1992) is 
presented in Figure 3. MEAA is the predominate metabolite in animals and the urinary 
levels of this compound are fairly abundant. It was found that male rats dosed with 14C-
labeled parent 2-(2-methoxyethoxy)ethanol excreted 68–70% of the label as the MEAA 
metabolite by means of ADH conversion (Cheever et al. 1988). The same study showed that 
only trace levels of 2-(2-methoxyethoxy)ethanol or methoxyethoxyacetaldehyde were 
detected in the urine. Further, cumulative excretion of 14C-tagged compounds showed rapid 
excretion (50% of administered dose excreted in 8 h) during rat oral dosing studies (Cheever 
et al. 1988). Study results from this laboratory also demonstrated that rat urinary MEAA is 
in the free form, not conjugated. Therefore, MEAA represents a viable candidate for 




This study was conducted on six USAF bases located within the continental United States. 
The participants were recruited with jobs rated as high, moderate, or low potential for jet 
fuel exposure. The high-exposure work-group category consisted of aircraft fuel-system 
maintenance workers, that is, those whose jobs included maintaining and repairing aircraft 
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fuel tanks (termed fuel cells), fuel lines, and associated structures. Workers were classified 
as “entrant,” “attendant,” or “runner,” based on the duties performed the day of observation 
during the study. The “entrant” had the job of actually entering the aircraft fuel tank or fuel 
cell wearing a supplied-air respirator. The “attendant” assisted the entrant and stayed outside 
the tank at all times. The “runner” stayed outside the tank and handled moving fuel-soaked 
foam that had been removed from the tank to a storage location or obtained tools for the 
“entrant.” Protective equipment was limited to forced air respirators, gloves, and cotton 
overalls for the “entrant.” The “attendant” was limited to cotton overalls. The moderate-
exposure group consisted of personnel who did not perform fuel-tank maintenance but 
conducted work that involved regular contact with jet fuel, such as fueling aircraft or 
maintaining fuel storage facilities. The low-exposure group consisted of workers whose jobs 
covered a wide variety of activities that did not require exposure to the jet fuel on the air 
force bases, and this group was used as a control group for the purpose of this study.
Collection of Urine Samples
Urine samples were collected from participants in the low (n = 61), moderate (n = 38), and 
high (n = 98) groups at the end of a 4-h work shift for urinary measurements. The samples 
were packed with frozen Blue Ice (Newell Rubbermaid, Inc., Atlanta, GA) and shipped to 
arrive within 24 h at the NIOSH laboratory. After arrival to the laboratory, samples were 
stored at −80°C until analysis.
Chemicals and Reagents
The BMA (S-benzylmercapturic acid, N-acetyl-S-benzyl-DL-cysteine, CAS number 
19542-77-9) reference standard was obtained from Cambridge Isotope Laboratories, Inc. 
(Andover, MA). The PMA (S-phenylmercapturic acid, N-acetyl-S-phenyl-DL-cysteine, CAS 
number 20640-68-0) reference standard was purchased from Tokyo Chemical Industry Co., 
Ltd. (TCI, Tokyo). The deuterated analogs, S-benzyl-d5-mercapturic acid and S-phenyl-d5-
mercapturic acid, were purchased from CDN Isotopes (Quebec, Canada). Standard 
compounds of (2-methoxyethoxy)acetic acid (MEAA, CAS number 16024-59-9) and the 
deuterated 2-butoxyacetic acid (d-BAA), used as an internal standard, were synthesized and 
described previously (Cheever et al. 1988; Brown et al. 2003). All other reagents used were 
analytical grade and are regularly available for laboratory use.
BMA and PMA HPLC-MS/MS Analysis
Urinary BMA and PMA levels were measured using a method previously validated and 
described (B’Hymer 2011). Briefly, a 4-ml aliquot of urine was spiked with deuterated 
analogs of BMA and PMA to act as internal standards. The target analytes were extracted by 
solid-phase extraction using Bond Elut C18 cartridges (Varian, Inc., Harbor City, CA) 
containing 500 mg of solid-phase bed. The analytes were recovered by acetone washes and 
evaporated to dryness. The dry extracts were dissolved in a 5/95/0.1% (v/v/v) solution of 
acetonitrile/water/acetic acid. A high-performance liquid chromatograph (HPLC) equipped 
with a tandem mass spectrometric detector (MS/MS) and a Zorbax RX C18 column (Agilent 
Technologies, Santa Clara, CA) with gradient elution (acetonitrile/water/acetic acid) was 
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used to analyze the samples and prepared standards. The limit of detection (LOD) for this 
method was 0.5 ng/ml for both BMA and PMA.
MEAA GC-MS Analysis
Urinary MEAA levels were measured using a method previously validated and described in 
the literature (B’Hymer et al. 2003; 2005b). Briefly, a 4-ml aliquot of urine was acidified 
with 12 N hydrochloric acid to pH 1–1.5, and the sample was spiked with d-BAA to act as 
an internal standard. The MEAA and internal standard were extracted by liquid–liquid 
extraction (LLE) using ethyl acetate, and the extraction solvent was evaporated to a 1-ml 
volume. Ethanol and concentrated sulfuric acid were used to react with the target analytes to 
form the corresponding ethyl esters. These products were extracted by LLE using methylene 
chloride and the methylene chloride solvent was reduced to a 1-ml volume by evaporation. 
Standard MEAA was used to spike unexposed urine at various levels and treated similarly to 
create the calibration curves for quantitation. A gas chromatograph (GC) equipped with a 
mass spectrometric detector and an HP-1 capillary column (Agilent Technologies, Santa 
Clara, CA) was used to analyze the sample and prepared standard solutions. The LOD for 
this method was 0.1 μg MEAA/ml urine.
Creatinine Determination
Urine samples were diluted 1:20 to measure creatinine concentrations using a Vitros 250 
Chemistry Analyzer (Ortho-Clinical Diagnostics, Rochester, NY), which employs a slide 
composed of a dry, multilayered analytical element coated on a polyester support (Findlay et 
al. 1985; Mauck et al. 1986). Creatinine measurements were calibrated with a 3-level set of 
standards, the highest being 17 mg/dl, which corresponds to a creatinine concentration of 
340 mg/dl for urine samples diluted 20-fold. Urine control pools (Bio-Rad Laboratories, 
Hercules, CA) and instrument Vitros Performance Verifier pools (Ortho-Clinical 
Diagnostics) were assayed in duplicate at the front, middle, and rear of each analytical run.
Statistical Analysis
Pairwise t-tests for unequal variances (Cochran and Cox 1950) were used to test for 
differences in mean concentrations between the workgroups. Analyses of the concentrations 
both not adjusted and adjusted for creatinine were performed. Measurements below the limit 
of detection (LOD, 0.5 ng/ml for BMA and PMA, 0.1 μg/ml for MEAA) were assigned a 
value of the limit of detection divided by the square root of 2. Hornung and Reed (1990) 
recommend this method for data that are lognormal distributed and not highly skewed. All 
calculations were made using SAS (Version 9.2, SAS Institute, Inc., Cary, NC).
RESULTS AND DISCUSSION
The BMA and PMA results of this study are summarized in Table 1 and are compared to a 
summary of MEAA data that were collected and reported previously (B’Hymer et al. 2012). 
The numbers of samples determined as positive for the presence of the BMA biomarker, that 
is, above the test method’s LOD (0.5 ng/ml), were 96 (98.0%), 37 (97.4%), and 58 (95.1%) 
for the high, moderates and low exposure work-group categories, respectively. The means of 
the three workgroups are also presented in Table 1 and graphically in Figure 4A. Toluene is 
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commonly encountered in the general environment from its use in most liquid fuels; 
therefore, its metabolite would be expected to be present in most of the individuals tested 
including the low exposure control group. Our modern motor vehicle-based society 
represents one of the main emission sources for toluene; thus, the study population, as well 
as the general population, undergoes a lifelong exposure to this chemical. Statistical analysis 
of the means for the three exposure workgroups was also undertaken (see Table 1). For 
BMA (ng/ml), the mean for the high group was greater than the mean for the low group, and 
this difference was statistically significant, while the difference between the means of the 
high and moderate group was not markedly different. In addition, when the mean urinary 
BMA levels were adjusted for creatinine (ng/mg creatinine), none of the means from the 
workgroups had differences of statistical significance. Owing to the high incidence of BMA 
metabolite being present in all samples (greater than 95%) and the lack of statistical 
significance detected between the means of the work groups after adjusting for creatinine, it 
can be safely concluded that BMA is not an ideal research tool for use as a biomarker of 
JP-8 exposure. It should also be noted that two individuals in the low exposure group had 
exceedingly high levels of urinary BMA and were dropped from the statistical analysis. 
Those two outlier values were 144 and 244 ng/ml; these values were confirmed by triplicate 
analysis. These two individuals had job descriptions obviously excluding them from 
exposure to JP-8 fuel. It was concluded that their exposure was from another environmental 
source, and this further weakened BMA for use as an accurate biomarker of JP-8 exposure.
The numbers of samples determined above the LOD for benzene metabolite PMA (0.5 
ng/ml) were 33 (33.7%), 9 (23.7%), and 12 (19.7%) for the high, moderate, and low 
exposure workgroup categories, respectively. The means of the three workgroups are also 
presented in Table 1 and graphically in Figure 4B. For PMA (ng/ml), the mean for the high 
group was greater than the means for the low and the moderate groups, and the differences 
were statistically significant in each case. However, after PMA was adjusted for creatinine 
(ng/mg creatinine), none of the workgroup means had statistically significant differences 
from one another. Benzene represents a fairly small component in the fuel and is quickly 
lost by expiration. Therefore, low urinary levels can be expected. Detection limits could 
have been reduced by a methodology utilizing extraction of the PMA metabolite from larger 
volumes of urine, but this would have led to a more expensive test. PMA can also be 
confounded by smoking since benzene is a minor product of tobacco combustion. 
Considering these factors and the evaluation of this study’s results, PMA was determined 
not to be an ideal tool for use as a biomarker of JP-8 exposure.
The numbers of samples determined above the LOD for MEAA (0.1 μg/ml) were 92 
(93.4%), 13 (34.2%), and 2 (3.3%) for the high, moderate, and low (control) exposure 
categories. The means of the three workgroups are also presented in Table 1 and graphically 
in Figure 4C. For MEAA (μg/ml), the mean for the high group was greater than the means of 
both the low and the moderate workgroup categories, and the differences were statistically 
significant in each case. The mean of the moderate exposure category was greater than the 
mean of the low category and was also statistically significant. Similar results of statistical 
significance were determined for the means of the workgroups when adjusting for 
creatinine. Again for MEAA, the mean (μg/ mg creatinine) of the high category was greater 
than the means for the low and the moderate workgroup categories, and these differences 
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were statistically significant in each case. The mean for the moderate category was greater 
than the mean for the low category and was statistically significant. Given the wide 
differences in the number of samples positive for the presence of MEAA and differences in 
the mean levels of urinary MEAA between the workgroups, MEAA was clearly 
demonstrated to be the best metabolite of the three evaluated for use as an accurate 
biomarker of JP-8 exposure. Also, comparison of the graphed data (see Figure 4) shows less 
concentration overlap of the three exposure categories for MEAA versus PMA and BMA, as 
well as the more significant difference in mean concentration values between the three 
exposure categories.
A discussion about creatinine urine levels is also in order. There were differences in the 
creatinine levels between the work groups. The mean levels of creatinine are shown in Table 
1, and the mean of the high exposure group was greater than other groups with statistically 
significant differences in each case. This was likely owing to dehydration and the increased 
physical workloads of participants in the high exposure group. The ACGIH, as well as other 
authorities, often uses creatinine-adjusted urinary levels for its BEI recommendations for 
this very reason. Creatinine adjustment is a traditional normalization procedure for many 
urinary analytes. For MEAA, its concentration in urine and that adjusted for creatinine show 
statistically similar results for the high, moderate, and low (control) exposure categories. 
This was not an unexpected result; the use of creatinine to normalize urinary analyte 
concentrations has been extensively reported to not necessarily improve correlation of dose 
to exposure for other urinary components (Allessio et al. 1985; Boeniger et al. 1993; Carrieri 
et al. 2001). Gaines et al. (2010) suggested the use of urine specific gravity for biomarker 
normalization as an alternative to creatinine. However, for the current JP-8 exposure study, 
creatinine-adjusted and nonadjusted values were the only normalization schemes 
investigated.
In summary, MEAA fits the qualities of a well-chosen biomarker of exposure. First, it 
appears to be relatively specific for the exposure of interest, namely, JP-8. There are few 
outside sources for its parent compound, unlike PMA and BMA from benzene and toluene, 
respectively. Second, MEAA is easily detectable at levels to distinguish exposure group 
categories of workers potentially exposed to JP-8. The high exposure category from this 
study had significantly higher levels of MEAA. The mean of the high exposure group was 
6.8 μg/ml, which was 68-fold greater than the LOD for the test procedure. Statistically, the 
MEAA means of the high, moderate, and low (control) exposure categories differ 
significantly for both creatinine-adjusted and nonadjusted concentration levels, unlike BMA 
and PMA. The gas chromatographic method (B’Hymer et al. 2003; 2005a) used in this study 
appears to have adequate MEAA sensitivity for its use as a biomarker of exposure. MEAA, 
therefore, is clearly associated with JP-8 exposure work-groups and has the potential for 
good predictive value, a desirable characteristic of a well-chosen biomarker of occupational 
exposure. Finally, the gas chromatographic test method is relatively inexpensive to use; 
liquid–liquid extraction was used with low-cost solvents and acid-catalyzed esterification, 
which avoided more expensive chemical derivatizing reagents.
However, there are obvious limitations for the use of MEAA as a biomarker of JP-8 
exposure. MEAA represents a metabolite of an additive component of JP-8; it does not 
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represent a metabolite of any of the other components within the fuel itself, and therefore 
has little clinical value for an individual. Obviously, the toluene and benzene biomarkers, 
BMA and PMA, would have a greater utility in the assessment of an individual’s exposure 
to the respective toxic parent compounds. The rate of skin penetration and bioavailability 
from inhalation would be different between the toxic components in JP-8, so that a single 
biomarker can only be used as an indirect biomarker for the other toxic components in the 
jet fuel. The metabolic conversion of 2-(2-methoxyethoxy)ethanol to MEAA is also fairly 
rapid; the half-life was determined to be approximately 8 h in various animal studies 
(Cheever et al. 1988; Daniel et al. 1991; Richards et al. 1993). MEAA, therefore, represents 
a biomarker of acute exposure to JP-8. Finally, MEAA production is based upon aldehyde 
dehydrogenase and alcohol dehydrogenase conversion metabolism. In this study, over 90% 
of the participants were ethnic Caucasian or African and had not consumed alcohol within 
24 h of the work shift and urine collection. MEAA would not be a useful biomarker of JP-8 
exposure in individuals with reduced metabolism, whether through mutations or hereditary 
factors, since the target urinary biomarker would not be produced.
CONCLUSIONS
This study evaluated and compared BMA, PMA, and MEAA for use as a biomarker of JP-8 
exposure. Despite BMA and PMA being described in outside studies as the preferred 
metabolites for toluene and benzene exposure, urinary MEAA analysis yielded the best 
statistical results to distinguish between workgroups having high, moderate, and low 
exposure to the JP-8 fuel. The proportions of positive measurements for MEAA (greater 
than the test method’s LOD [0.1 μg/ml]) were 93.9%, 34.2%, and 3.3% for the high, 
moderate, and low exposure categories, respectively. The toluene metabolite BMA was 
present in most urine samples and was probably due to the widespread existence of toluene 
in the general environment. Therefore, BMA was not a useful biomarker for JP-8 exposure, 
but may be used as biomarker for general exposure to toluene. The benzene metabolite PMA 
likely would not be a useful metabolic biomarker for JP-8 exposure owing to the low 
concentration benzene in the batches of fuel and the need for more sensitive instrumentation 
or a greater expense for laboratory testing. MEAA, therefore, represents an ideal research 
tool for use as a biomarker of JP-8 exposure with a sensitive and relatively low-cost analysis 
methodology.
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The metabolic formation of S-benzylmercapturic acid (BMA) from toluene, a common 
component in jet fuel. BMA was one of the metabolites evaluated in this study.
B’Hymer et al. Page 11














The metabolic formation of S-phenylmercapturic acid (PMA) from benzene, a common 
component in jet fuel. PMA was one of the metabolites evaluated in this study.
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The metabolic formation of (2-methoxyethoxy)acetic acid (MEAA) from the JP-8 anti-icing 
agent 2-(2-methoxyethoxy)ethanol. MEAA is one of the metabolites evaluated in this study.
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Comparisons of urinary metabolite levels in low, moderate, and high jet-fuel exposure 
categories. All urinary concentrations are on a log10 scale. (A) BMA is measured in ng/ml. 
(B) PMA is measured in ng/ml. (C) MEAA is measured in μg/ml.
B’Hymer et al. Page 14










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Toxicol Environ Health A. Author manuscript; available in PMC 2016 January 04.
